Clinical Trial: Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053436) titled 'Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma' on May 28.

Brief Summary: The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

Study Start Date: Oct. 01, 2025

Study Type: INTERVEN...